PMID- 29632293
OWN - NLM
STAT- MEDLINE
DCOM- 20190510
LR  - 20221222
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 70
IP  - 4
DP  - 2018 Apr
TI  - [Immune Checkpoint Inhibitors and Neuromuscular Adverse Events].
PG  - 461-466
LID - 10.11477/mf.1416201019 [doi]
AB  - Neuromuscular adverse events (AEs) in cancer patients treated with immune 
      checkpoint inhibitors (ICIs) are characterized by diverse clinical subsets. The 
      general features of neuromuscular AEs have remained elusive due to its low 
      frequency, ranging from 1-2% of cancer patients undergoing ICIs therapy. The 
      diseases affect the central nervous system, peripheral nerves, neuromuscular 
      junction, and muscle. Disease onset and progression may be rapid with a critical 
      clinical course. The clinical presentation may differ from that of patients whose 
      symptoms are unrelated to drugs. Headache, dizziness, and dysgeusia are 
      relatively common and mild treatment-related AEs. In contrast, immune-related 
      AEs, such as autoimmune encephalitis, demyelinating polyneuropathy, myasthenia, 
      and myositis are more serious conditions. There is a strong correlation between 
      ICIs and myasthenia, myositis, and myocarditis. Immune-modulating medication is 
      generally effective for neuromuscular AEs. However, there are guidelines for 
      treatment, and checkpoint inhibitor therapy should be withheld until the 
      pathophysiology of the AEs is defined. Both CD8(+) cytotoxic T cells and 
      autoantibodies are involved in the pathogenesis of neuromuscular AEs. Therefore, 
      understanding the mechanisms of neuromuscular AEs is necessary to alleviate the 
      symptoms associated with ICIs therapy in cancer patients.
FAU - Suzuki, Shigeaki
AU  - Suzuki S
AD  - Department of Neurology, Keio University School of Medicine.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
RN  - 0 (Autoantibodies)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Autoantibodies/*immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Disease Progression
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Myasthenia Gravis/complications/immunology
MH  - Myocarditis/complications/immunology
MH  - Myositis/complications/immunology
MH  - Neoplasms/complications/*immunology
EDAT- 2018/04/11 06:00
MHDA- 2019/05/11 06:00
CRDT- 2018/04/11 06:00
PHST- 2018/04/11 06:00 [entrez]
PHST- 2018/04/11 06:00 [pubmed]
PHST- 2019/05/11 06:00 [medline]
AID - 1416201019 [pii]
AID - 10.11477/mf.1416201019 [doi]
PST - ppublish
SO  - Brain Nerve. 2018 Apr;70(4):461-466. doi: 10.11477/mf.1416201019.